Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant

Experimental Dermatology

Volumn 10, Issue 3, 2001, Pages 161-167

  Hunger, R E ^a   Brand, C U ^a   Streit, M ^a   Eriksen, J A ^b   Gjertsen, M K ^c   Saeterdal, I ^c   Braathen, L R ^a   Gaudernack, G ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b STATOIL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Active immunotherapy; Cancer vaccines; Melanoma; ras peptides

Indexed keywords

CANCER VACCINE; PEPTIDE; RAS PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CELL CLONING; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURFACE; CELL TRANSFORMATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; DELAYED HYPERSENSITIVITY; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HLA TYPING; HUMAN; IMMUNOGENICITY; MALE; MELANOMA; ONCOGENE RAS; PHASE 1 CLINICAL TRIAL; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODY FORMATION; CELL DIVISION; CLONE CELLS; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; INJECTIONS, INTRADERMAL; MALE; MELANOMA; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS P21(RAS); SKIN NEOPLASMS; T-LYMPHOCYTES; VACCINATION;

EID: 0035017385     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0625.2001.010003161.x     Document Type: Article

References (31)

1. Prospective study of the incidence of melanoma in the Paris region in 1994. The PETRI Melanoma Group
2. Incidence of malignant melanoma of the skin in Norway, 1955-1989: Associations with solar ultraviolet radiation, income and holidays abroad
3. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century
4. Cancer Research Campaign health education programme to promote the early detection of cutaneous malignant melanoma. II. Characteristics and incidence of melanoma
5. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients
6. Epidemiology of malignant melanoma in central Europe: Risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society
7. Prognostic clinical and pathologic features
8. Human tumor antigens recognized by T cells
9. Advances in specific immunotherapy of malignant melanoma
10. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
11. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
12. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
13. + T cells in the antitumor immune response
14. + T cell responses in antitumor immunity
15. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene
16. Regulation of ras-mediated signaling: More than one way to skin a cat
17. Ras-effector interactions, the problem of specificity
18. Activated ras: Yet another player in melanoma?
19. Relevance of UV-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma
20. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-Leu61)
21. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras
22. T-cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA
23. Overlapping epitopes encompassing a point mutation (12 Gly-Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells
24. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
25. Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination
26. T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides
27. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
28. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines
29. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
30. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi
31. + T lymphocytes, generated by mutant p21-ras (12Va1) peptide vaccination of a patient, recognize 12Va1-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation